Skip to content

Study · Animal study (in vivo) · mouse · 2014

9 results

Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.

Botte DA, Noronha IL, Malheiros DM, Peixoto TV, de Mello SB

Clinical and experimental immunology1 Aug 2014Cited by 23 (Europe PMC)

PMID24666423 (opens in a new tab)DOI10.1111/cei.12336 (opens in a new tab)PepBankPUB-24666423
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment reduced arthritis scores by 70%.

    In plain wordsIn mice with lupus-like disease, NDP-MSH reduced joint inflammation scores.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseArthritis score
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Measurements

    Arthritis score reduction
    70%
    NDP-MSH vs saline

    Source sentences

    Summary
    NDP-MSH treatment reduced arthritis scores by 70% and also diminished IgG1 and IgG2a levels and ANA incidence.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment diminished IgG1 levels.

    In plain wordsIn mice with lupus-like disease, NDP-MSH lowered IgG1 antibody levels.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreasePlasma IgG1 level
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    NDP-MSH treatment reduced arthritis scores by 70% and also diminished IgG1 and IgG2a levels and ANA incidence.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment diminished IgG2a levels.

    In plain wordsIn mice with lupus-like disease, NDP-MSH lowered IgG2a antibody levels.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreasePlasma IgG2a level
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    NDP-MSH treatment reduced arthritis scores by 70% and also diminished IgG1 and IgG2a levels and ANA incidence.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment diminished the incidence of anti-nuclear antibodies.

    In plain wordsIn mice with lupus-like disease, NDP-MSH lowered how often anti-nuclear antibodies appeared.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseAnti-nuclear antibody incidence
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    NDP-MSH treatment reduced arthritis scores by 70% and also diminished IgG1 and IgG2a levels and ANA incidence.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment reduced glomerular cellularity by 50%.

    In plain wordsIn mice with lupus-like disease, NDP-MSH reduced the number of cells in the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular cellularity
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Measurements

    Glomerular cellularity reduction
    50%
    NDP-MSH vs saline

    Source sentences

    Summary
    In the glomerulus, NDP-MSH treatment reduced cellularity by 50% together with reducing IgG deposits, and expression levels of α-SMA, iNOS and CRF were also all decreased.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment reduced IgG deposits in the glomerulus.

    In plain wordsIn mice with lupus-like disease, NDP-MSH reduced antibody deposits in the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular IgG deposits
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    In the glomerulus, NDP-MSH treatment reduced cellularity by 50% together with reducing IgG deposits, and expression levels of α-SMA, iNOS and CRF were also all decreased.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment decreased glomerular expression of alpha-SMA.

    In plain wordsIn mice with lupus-like disease, NDP-MSH lowered a scarring marker, alpha-SMA, in the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular alpha-SMA expression
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    In the glomerulus, NDP-MSH treatment reduced cellularity by 50% together with reducing IgG deposits, and expression levels of α-SMA, iNOS and CRF were also all decreased.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment decreased glomerular expression of iNOS.

    In plain wordsIn mice with lupus-like disease, NDP-MSH lowered iNOS, an inflammation enzyme, in the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular iNOS expression
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    In the glomerulus, NDP-MSH treatment reduced cellularity by 50% together with reducing IgG deposits, and expression levels of α-SMA, iNOS and CRF were also all decreased.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with pristane-induced lupus, NDP-MSH treatment decreased glomerular expression of corticotrophin-releasing factor.

    In plain wordsIn mice with lupus-like disease, NDP-MSH lowered corticotrophin-releasing factor in the kidney filters.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseGlomerular CRF expression
    Study

    mousen: not reported in source

    Pristane-induced lupus in female BALB/cAn mice
    Comparator
    Saline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.25 mg/kg daily · intraperitoneal · 180 daysAs given in this study (mouse).

    Source sentences

    Summary
    In the glomerulus, NDP-MSH treatment reduced cellularity by 50% together with reducing IgG deposits, and expression levels of α-SMA, iNOS and CRF were also all decreased.
    2 context sentences
    Summary · context
    Here we employed female Balb/cAn mice in which lupus was induced by pristane.
    Summary · context
    Groups of lupus animals were treated daily with the α-MSH analogue [Nle4, DPhe7]-α-MSH (NDP-MSH) (1·25 mg/kg) injected intraperitoneally or saline for 180 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.